In the original article, there was a mistake in Figure 5 as published. The symbols (*, **, ***, ns) of statistic differences in Figures 5B–F were wrongly labeled. The wrongly labeled Figure 5 was uploaded by accident when submitting the corrections of proof. The corrected Figure 5 appears below.
FIGURE 5.
A combination of SolB and WeD treatment dramatically inhibits hepatic fibrosis and injury in CCL4-induced hepatic fibrosis mice. (A) Images of livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB(40 mg/kg) and WeD(20 mg/kg). Representative micrographs of liver H&E staining, Sirius red, Masson and α-SMA staining were shown. Scale bars represent 50 μm. (B–D) Quantitative results of Sirius red(B), Masson(C) and α-SMA(D) staining sections. (E) Serum level of hydroxyproline of control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. (F) Quantitative PCR analysis of mRNA levels of α-SMA in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. (G) Western blot analysis of Collagen1, p-Smad3, Smad2/3, p-IκBα, IκBα and GAPDH in livers from control, CCL4-induced hepatic fibrosis mice, CCL4-induced hepatic fibrosis mice treated with colchicine(0.2 mg/kg), SolB(40 mg/kg), WeD(20 mg/kg) or combination of SolB and WeD. Data are expressed as Mean ± SD (n = 8 or 3 mice). Statistics differences were analyzed using One-way ANOVA followed by Tukey’s post hoc tes: *p < 0.05, **p < 0.01, ***p < 0.001. NS, no significance.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.